251 related articles for article (PubMed ID: 19965674)
21. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.
Chauhan D; Ray A; Viktorsson K; Spira J; Paba-Prada C; Munshi N; Richardson P; Lewensohn R; Anderson KC
Clin Cancer Res; 2013 Jun; 19(11):3019-31. PubMed ID: 23584492
[TBL] [Abstract][Full Text] [Related]
22. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
Chauhan D; Neri P; Velankar M; Podar K; Hideshima T; Fulciniti M; Tassone P; Raje N; Mitsiades C; Mitsiades N; Richardson P; Zawel L; Tran M; Munshi N; Anderson KC
Blood; 2007 Feb; 109(3):1220-7. PubMed ID: 17032924
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
[TBL] [Abstract][Full Text] [Related]
24. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
25. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Tian Z; D'Arcy P; Wang X; Ray A; Tai YT; Hu Y; Carrasco RD; Richardson P; Linder S; Chauhan D; Anderson KC
Blood; 2014 Jan; 123(5):706-16. PubMed ID: 24319254
[TBL] [Abstract][Full Text] [Related]
26. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Fuchs O; Provaznikova D; Marinov I; Kuzelova K; Spicka I
Cardiovasc Hematol Disord Drug Targets; 2009 Mar; 9(1):62-77. PubMed ID: 19275578
[TBL] [Abstract][Full Text] [Related]
27. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
[TBL] [Abstract][Full Text] [Related]
28. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
Rychak E; Mendy D; Shi T; Ning Y; Leisten J; Lu L; Miller K; Narla RK; Orlowski RZ; Raymon HK; Bjorklund CC; Thakurta A; Gandhi AK; Cathers BE; Chopra R; Daniel TO; Lopez-Girona A
Br J Haematol; 2016 Mar; 172(6):889-901. PubMed ID: 26914976
[TBL] [Abstract][Full Text] [Related]
29. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Canella A; Cordero Nieves H; Sborov DW; Cascione L; Radomska HS; Smith E; Stiff A; Consiglio J; Caserta E; Rizzotto L; Zanesi N; Stefano V; Kaur B; Mo X; Byrd JC; Efebera YA; Hofmeister CC; Pichiorri F
Oncotarget; 2015 Oct; 6(31):31134-50. PubMed ID: 26429859
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
van der Spek E; Bloem AC; Lokhorst HM; van Kessel B; Bogers-Boer L; van de Donk NW
Leuk Res; 2009 Jan; 33(1):100-8. PubMed ID: 18621417
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B
J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742
[TBL] [Abstract][Full Text] [Related]
32. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Santo L; Hideshima T; Cirstea D; Bandi M; Nelson EA; Gorgun G; Rodig S; Vallet S; Pozzi S; Patel K; Unitt C; Squires M; Hu Y; Chauhan D; Mahindra A; Munshi NC; Anderson KC; Raje N
Clin Cancer Res; 2011 May; 17(10):3259-71. PubMed ID: 21430070
[TBL] [Abstract][Full Text] [Related]
33. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
35. Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.
Leiba M; Jakubikova J; Klippel S; Mitsiades CS; Hideshima T; Tai YT; Leiba A; Pines M; Richardson PG; Nagler A; Anderson KC
Br J Haematol; 2012 Jun; 157(6):718-31. PubMed ID: 22533681
[TBL] [Abstract][Full Text] [Related]
36. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
37. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
Chauhan D; Li G; Podar K; Hideshima T; Shringarpure R; Catley L; Mitsiades C; Munshi N; Tai YT; Suh N; Gribble GW; Honda T; Schlossman R; Richardson P; Sporn MB; Anderson KC
Blood; 2004 Apr; 103(8):3158-66. PubMed ID: 15070698
[TBL] [Abstract][Full Text] [Related]
38. A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.
Ray A; Tian Z; Das DS; Coffman RL; Richardson P; Chauhan D; Anderson KC
Leukemia; 2014 Aug; 28(8):1716-24. PubMed ID: 24476765
[TBL] [Abstract][Full Text] [Related]
39. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
Raje N; Kumar S; Hideshima T; Ishitsuka K; Chauhan D; Mitsiades C; Podar K; Le Gouill S; Richardson P; Munshi NC; Stirling DI; Antin JH; Anderson KC
Blood; 2004 Dec; 104(13):4188-93. PubMed ID: 15319277
[TBL] [Abstract][Full Text] [Related]
40. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
